Sign in

RxSight (RXST)

RXST Q3 2024: Utilization Growth Slows, Q4 Up 8% YoY

Reported on Nov 7, 2024 (After Market Close)
Pre-Earnings Price$50.85Last close (Nov 7, 2024)
Post-Earnings Price$47.03Open (Nov 8, 2024)
Price Change
$-3.82(-7.51%)
  • Strong Utilization and Adoption Trends: Q&A responses highlighted that RxSight’s LAL implantation utilization per LDD is growing steadily across practices, with newer accounts ramping up quickly to established levels, suggesting increasing clinical adoption and favorable outcomes.
  • Compelling Capital Economics: The management emphasized a rapid payback period of approximately 6 months on the LDD investment and consistent, stable pricing for both LAL and LDD, which makes the capital expenditure attractive and supports repeat purchases.
  • Broadening Market Reach via Optometrist Engagement: The executives outlined initiatives to educate the approximately 50,000 U.S. optometrists, positioning them to drive referrals and further market penetration, thereby expanding the overall addressable market for RxSight’s products.
  • Hurricane impact risk: The earnings call Q&A noted that hurricanes contributed to lost surgical days in Q3, potentially affecting revenue and procedure volumes, especially in key markets like Florida.
  • Deceleration in utilization growth: Analysts highlighted a potential deceleration in LAL utilization growth, with Q4 projected to show an 8% year-over-year increase compared to previous quarters in the high teens to low 20s, which could indicate a slowdown as market saturation occurs.
  • Challenges with market penetration and adoption: Questions regarding maintaining pricing, securing new capital equipment placements, and expanding market share beyond the current ~10% benchmark suggest that achieving higher and sustainable adoption rates could be challenging in a competitive environment.
  1. Margin Outlook
    Q: Is gross margin stable post‑2024?
    A: Management expects gross margins to remain around 70–71% thanks to ongoing cost efficiencies and a favorable shift in product mix.

  2. Capital & LDD Growth
    Q: How is LDD placement growing?
    A: Strong capital demand is evident with robust LDD placements delivering a return on investment in about 6 months.

  3. Pricing Stability
    Q: Will product pricing remain unchanged?
    A: Management is confident in holding the $1,000 LAL price and preserving steady LDD ASPs despite market pressures.

  4. Revenue Guidance 2025
    Q: Any early guidance for 2025?
    A: While no specific numbers were provided, management remains bullish on sustained growth driven by compelling clinical results.

  5. Utilization Trends
    Q: Why is utilization growth moderating?
    A: As the installed base expands, percentage growth naturally moderates even though overall LAL utilization stays strong.

  6. Global Expansion
    Q: When will international approvals arrive?
    A: Regulatory approvals in Asia and Europe are expected in the coming months, a key step in expanding global market share.

  7. Active Surgeons
    Q: What’s the average surgeon count per LDD?
    A: The average number of active physicians per LDD is roughly 1.5–1.6, varying with practice size.

  8. International Sales Channels
    Q: How will international sales be managed?
    A: A market-specific approach is planned; some regions like Canada will use distributors, while others will rely on direct sales.

  9. Optometrist Outreach
    Q: How is the optometrist program progressing?
    A: The program is gaining momentum as optometrists educate patients and refer them, supporting wider premium IOL adoption.

  10. Seasonality Effects
    Q: Was seasonality a factor this quarter?
    A: Yes, more pronounced seasonality—primarily due to extended doctor vacations—affected LAL volumes, though LDD sales stayed consistent.

Research analysts covering RxSight.